글로벌 기관염 치료 시장 – 2030년까지의 산업 동향 및 예측

 기관염 치료 시장 분석 및 규모

기관염은 기관이 작고 붓기로 인해 더 쉽게 막히기 때문에 주로 어린아이에게 영향을 미칩니다. 여아보다 남아에게 더 흔합니다. 담배의 만성 소비 증가는 시장 성장을 증가시키는 중요한 요인입니다. 박테리아성 기관염은 드물며 영국과 호주에서 연간 발병률이 10만 명의 어린이당 0.1건 미만으로 예상됩니다.  

Data Bridge Market Research는 2023-2030년 예측 기간 동안 기관염 치료 시장의 성장률을 분석합니다. 기관염 치료 시장의 예상 CAGR은 언급된 예측 기간 동안 약 4.10%인 경향이 있습니다. 시장은 2022년에 55억 달러로 평가되었으며 2030년까지 69억 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

기관염 치료 시장 범위 및 세분화

Market Definition

Tracheitis is an upper tract respiratory infection characterized by mucosal inflammation of the trachea, a transits duct that carries air to the lungs from the upper airways (throat, nose, ears). It is very rare and mostly affects the adult population. Patients with tracheitis experience chest pain, persistent cough, shortness of breath, coughing, blue lips and others.

Tracheitis Treatment Market Dynamics

Drivers

• Growing Prevalence of COPD

Increased prevalence of COPD is a main factor driving the market growth. According to the June 2021 update WHO, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, causing 3.23 million deaths in 2019. Therefore, the increasing burden of COPD leads to increasing demand for tracheitis treatment.

• Rising Incidence of Smoking

Smoking remains the top cause of preventable disease, and death in the U.S., accounting for more than 480,000 deaths  each year, or about 1 in 5 deaths. Current cigarette smoking was highest among people aged 25–44 and 45–64. Therefore, in return, it leads to tracheitis treatment and can create opportunities for the market growth

Opportunities

• Advanced Clinical Research and Innovative Strategies

Numerous market players are engaged in implementing strategic initiatives, thus contributing to market growth. For instance, Beta2‐agonists was developed as clinicians suspect numerous patients also have reversible airflow restriction (as seen in asthma or chronic obstructive pulmonary disease (COPD)) contributing to the symptoms.

Restraints/Challenges

• Lack of Awareness

Lack of patient awareness about the disease and its differentiated symptoms could limit the growth of the global tracheitis treatment market during the forecast period.

• High Cost

The huge expenditure required for treating tracheitis treatment hamper the market growth. There are different types of drugs that cost a higher price and also injections that lead to the market restriction.

This tracheitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tracheitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Tracheitis Treatment Market Scope

The tracheitis treatment market is segmented on the basis of strain type, indication, treatment, medication type, drugs, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Strain Type

• Streptococcus Pneumoniae
• Staphylococcus Aeureus
• Others

Indication

• Tracheobronchitis
• Bacterial Croup
• Laryngotracheobronchitis

Treatment

• Endotracheal intubation
• Antibiotics
• Others

Medication Type

• Prescription Drugs
• Over-the-Counter Drugs

Drugs

• Noscapine – Chlorhexidine
• Camiter
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospitals
• Specialty Clinics
• Others

Tracheitis Treatment Market Regional Analysis/Insights

The tracheitis treatment market is analyzed and market size insights and trends are provided by strain type, indication, treatment medication type, drugs, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the tracheitis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America accounts the largest market share due to rise in the prevalence of the disease, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people in this region.

Asia-Pacific is likely to hold for the largest market share over coming years for the tracheitis treatment market due to an increase in the research & development and strong government support in this region. 

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 글로벌 기관염 치료 시장 점유율 분석

기관염 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 기관염 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

기관염 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• SAVAL Pharmaceuticals (미국)
• 게놈 생명공학 Pvt. Ltd (인도)
• Vertex Pharmaceuticals Incorporated (미국)
• 노바티스 AG(스위스)
• GSK plc (영국)
• 애벗(미국)
• 아스트라제네카(영국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 마일런 NV(미국)
• Cipla Inc(인도)
• ARMS Pharmaceutical LLC(미국)

SKU-46321